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Immune parameters are elevated in psychosis, but it is unclear 
whether alterations are homogenous across patients or het-
erogeneity exists, consistent with the hypothesis that immune 
alterations are specific to a subgroup of patients. To address 
this, we examine whether antipsychotic-naïve first-episode psy-
chosis patients exhibit greater variability in blood cytokines, 
C-reactive protein, and white cell counts compared with con-
trols, and if group mean differences persist after adjusting for 
skewed data and potential confounds. Databases were searched 
for studies reporting levels of peripheral immune parameters. 
Means and variances were extracted and analyzed using mul-
tivariate meta-analysis of mean and variability of differences. 
Outcomes were (1) variability in patients relative to controls, 
indexed by variability ratio (VR) and coefficient of varia-
tion ratio (CVR); (2) mean differences indexed by Hedges g; 
(3) Modal distribution of raw immune parameter data using 
Hartigan’s unimodality dip test. Thirty-five studies reporting 
on 1263 patients and 1470 controls were included. Variability 
of interleukin-6 (IL6) (VR = 0.19), tumor necrosis factor-α 
(TNFα) (VR = 0.36), interleukin-1β (VR = 0.35), interleukin-4 
(VR = 0.55), and interleukin-8 (VR = 0.28) was reduced in 
patients. Results persisted for IL6 and IL8 after mean-scaling. 
Ninety-four percent and one hundred percent of raw data were 
unimodally distributed in psychosis and controls, respectively. 
Mean levels of IL6 (g = 0.62), TNFα (g = 0.56), interferon-γ 
(IFNγ) (g = 0.32), transforming growth factor-β (g = 0.53), 
and interleukin-17 (IL17) (g = 0.48) were elevated in psycho-
sis. Sensitivity analyses indicated this is unlikely explained by 
confounders for IL6, IFNγ, and IL17. These findings show 
elevated cytokines in psychosis after accounting for confounds, 
and that the hypothesis of an immune subgroup is not sup-
ported by the variability or modal distribution.
Keywords:  inflammation/immune/psychosis/variability
Introduction
Schizophrenia and related psychotic disorders have a 
worldwide lifetime prevalence of approximately 1%.1 
They are leading contributors to global disease burden, 
partly because of inadequate response to antipsychotic 
treatment in many patients.2 A greater understanding of 
illness pathophysiology is required to identify novel ther-
apeutic targets, and develop biologically informed diag-
noses.3 Converging lines of evidence, including genetic, 
postmortem, and preclinical data, suggest immune dys-
regulation may play a role in psychosis pathogenesis.4–22 
Supporting this, meta-analyses have shown raised lev-
els of soluble interleukin-2 receptor (sIL2R), interleu-
kin-6 (IL6), interleukin-8 (IL8), interleukin-10 (IL10), 
interferon-γ (IFNγ), transforming growth factor-β 
(TGFβ), tumor necrosis factor-α (TNFα), C-reactive 
protein (CRP) and white cell counts in both antipsy-
chotic-naïve first episode psychosis (FEP) and chronic 
medicated schizophrenia compared with controls, with 
large effect sizes.16–22
It has been hypothesized that there are biological sub-
types of psychosis,3,23–25 with immune alterations seen 
only in a proportion of patients and potentially linked 
to poor response to treatment.26,27 In addition to inflat-
ing effect sizes for mean differences between patients and 
controls, the presence of an immune subgroup would be 
expected to lead to increased immune parameter vari-
ability in patients. We therefore set out to assess this by 
performing a meta-analysis of variability, as previously 
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employed to examine regional brain structural variability 
in FEP.28 If  immune alterations are seen only in a sub-
group of patients then greater immune measure variability 
in patients relative to controls would be predicted, reflect-
ing heterogeneity in immune dysregulation. Conversely, if  
immune alterations are a core component of the patho-
physiology of psychosis, reduced immune variability in 
patients compared with controls would be predicted, 
reflecting homogeneity in immune dysregulation. This 
approach could however fail to identify subgroups of 
data contained within the overall data distribution (eg, 
a bimodal distribution). To address this, we also set out 
to examine distribution of raw immune parameter data 
in patients to assess for a multimodal distribution. The 
presence of latent immune subgroups within the healthy 
control group27,29 could also influence variability analy-
ses, thus we also set out to assess for multimodality in 
controls.
Mean differences in immune parameters between 
patients and controls reported in previous meta-anal-
yses16–22 could be influenced by physiological and envi-
ronmental confounders, eg, body mass index (BMI),30,31 
smoking,32 age,33 gender,34 hypothalamic–pituitary–adre-
nal (HPA) axis activity,35 and ethnicity.36 Moreover, mean 
meta-analytic differences may be influenced by data-skew. 
Many immune parameters are physiologically present at 
low concentrations, and poor assay sensitivity at these 
levels can result in a floor effect.37 This results in positive 
skew, potentially inflating group differences.38,39 Indeed, 
over half  the data sets included in previous meta-anal-
yses examining immune parameters in psychosis show 
evidence of significant skew,26,40–60 and the Cochrane 
Collaboration recommends that meta-analyses based 
on means are appropriate only for data that are at least 
approximately normally distributed.61 Thus, we also set 
out to assess if  mean differences in immune parameters 
between patients and controls were robust to sensitiv-
ity analyses focusing on studies that matched for physi-
ological/environmental confounds, and with skewed data 
removed.
To our knowledge, this article represents the first vari-
ability meta-analysis of immune parameters, the first 
study to examine distribution of multiple raw immune 
parameter data sets, and the first meta-analysis of mean 
differences to comprehensively examine the role of con-
founders and data-skew in individuals with psychosis 
compared with controls.
Methods
Selection Procedures
A systematic review was performed according to 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA)62 and Meta-Analysis of 
Observational Studies in Epidemiology (MOOSE)63 
guidelines (supplementary eAppendix 1), following an a 
priori protocol (supplementary eAppendix 2). Two review-
ers (TP and EO) independently searched the Pubmed, 
EMBASE, and PsycINFO databases from inception to 
November (week 2) 2017 using the following keywords: 
(lymphocytes or T-lymphocytes or B-lymphocytes or 
monocytes or macrophages or inflammat* or IL-* or 
cytokine or CRP or C-reactive protein or hs-CRP or 
hsCRP or interleukin* or tumour necrosis factor or 
transforming growth factor or interferon) and (schizo-
phren* or psycho*) and (first episode or early or antipsy-
chotic* or drug* or neuroleptic*). Only English-written 
studies were considered. Abstracts were screened, and 
full texts of studies retrieved. Where texts were unavail-
able, authors were contacted and manuscripts requested. 
We also requested raw data sets from authors, and where 
appropriate, clarification as to whether patients were 
antipsychotic naïve. TP and EO selected final studies for 
meta-analysis.
Selection Criteria
Inclusion criteria were (1) patients with FEP, defined 
either as first treatment contact/patients recruited from 
FEP services in line with previous studies64; (2) anti-
psychotic-naïve; (3) a healthy control group; (4) studies 
assessing blood cytokines/cytokine receptors, C-reactive 
protein (CRP) (plasma/serum samples), and white cell 
counts. The rationale behind focusing on antipsychotic-
naïve FEP was to minimize confounding effects of med-
ication and lifestyle habits (eg, diet/exercise) associated 
with chronic psychotic illness65,66 that may directly (eg, 
antipsychotics)67 or indirectly (eg, diet/exercise)30,31 alter 
immune parameters. Exclusion criteria were (1) genetic 
studies (incomplete translation and post-translational 
modification means mRNA levels cannot be assumed 
to reflect protein levels)68; (2) in vitro studies; (3) stud-
ies examining stimulated cytokine levels; (4) substance/
medication-induced psychosis; (5) absence of data allow-
ing mean and/or standard deviation calculation.
Recorded Variables
Data were extracted as follows: author, publication year, 
matching criteria, and mean (with standard deviation) 
measure of immune parameter (table 1 and supplementary 
eTable 1). See supplementary eAppendix 3 for further details.
Statistical Analysis
As many studies reported on several parameters, multi-
variate meta-analysis was used, enabling simultaneous 
estimation of summary effect sizes across all immune 
parameters, reducing risk of false positives due to mul-
tiple comparisons.83 For all meta-analyses, an omnibus 
test evaluated significance of model coefficients across 
immune parameters. Where the omnibus test was signif-
icant, we tested the effect separately for each parameter. 
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Table 1. Summary of the Designs and Sample Characteristics of the Studies Included in the Meta-analyses
Study Patient, N Control, N Diagnoses Patient Age, Mean (SD)
Immune 
Parameter Matching
Ajami et al40 8 26 Schizophrenia Not specified IL2, IL10, TNFα Not specified
Akiyama69 14 27 Schizophrenia 34.4 (14.0) sIL2R, IL6 Age, gender
Borovcanin et al41 84 35 First-episode psychosis 33.6 (8.8) TGFβ Age
De Berardis et al70 30 30 Schizophrenia (25)
Schizophreniform 
disorder (2)
Brief  psychotic disorder 
(1)
Delusional disorder (2)
25.9 (6.0) CRP Age, gender
Devanarayanan et al42 22 40 Schizophrenia 29.0 (4.0) CRP Age, gender
Di Nicola et al43 5 24 First-episode psychosis 28.1 (1.1) IL1β, IL2, IL4, 
IL6, IL8, IL10, 
TNFα, IFNγ
Age, gender, 
BMI, ethnicity
Ding et al44 69 60 Schizophrenia 27.5 (7.8) IL6, IL17, IFNγ Age, gender, 
BMI, smoking
El Kissi et al45 10 27 Schizophrenia Not specified IL17, IFNγ, 
TGFβ
Age, gender
Fawzi and Said46 108 200 Schizophrenia 27.2 (10.6) CRP Age, gender, 
BMI, smoking, 
ethnicity
Fernandez-Egea et al47 50 50 Schizophrenia (35)
Schizophreniform 
disorder (8)
Brief  psychotic disorder 
(4)
Delusional disorder (2)
Psychosis NOS (1)
29.4 IL6, CRP Age, gender, 
BMI, smoking, 
ethnicity, 
cortisol
Ganguli and Rabin60 4 57 Schizophrenia Not specified sIL2R Not specified
Ganguli et al71 24 110 Schizophrenia
Schizoaffective disorder
Not specified IL6 Age, gender
Ganguli et al72 33 33 Schizophrenia Not specified IL2 Age, gender
Garcia-Rizo et al48 75 80 First-episode 
(nonaffective) psychosis
28.0 (6.2) Total lymphocyte 
count
Age, gender, 
BMI, smoking
Gattaz et al73 10 11 Schizophrenia Not specified IL2, IFNγ Age, gender
Haring et al49
Balotsev et al74
38 37 First-episode psychosis 25.4 (0.9) IL1β, IL2, IL4, 
IL6, IL8, IL10, 
IFNγ, TNFα
Age, gender, 
BMI, smoking
Hepgul et al50 4 45 First-episode psychosis Not specified CRP Not specified
Kalmady et al75 25 33 Schizophrenia 29.9 (5.7) IL6 Age, gender
Karanikas et al51 25 23 Schizophrenia (1)
Schizophreniform 
disorder (16)
Brief  psychotic disorder 
(4)
Psychotic disorder NOS 
(4)
25.5 (5.4) IL1b, IL2, IL4, 
IL8, IL10, IFNγ, 
TNFα
Age, BMI, 
cortisol
Kubistova et al52 25 25 Schizophrenia 32.3 (7.0) IL6, IL8, IL10, 
TNFα
Age, gender
Masserini et al53 7 37 Schizophrenia
Schizophreniform 
disorder
Not specified Total lymphocyte 
count
Not specified
Mondelli et al26 3 36 First-episode psychosis Not specified IL1β, IL2, IL4, 
IL6, IL8, IL10, 
TNFα, IFNγ
Age, gender
Noto et al54
Noto et al55
Brinholi et al56
156 58 Schizophrenia 
Schizophreniform 
disorder
Brief  psychotic disorder
Psychosis NOS
Mania with psychosis
26.2 (7.6) IL4, IL6, IL10, 
IL17, TNFα, 
IFNγ
Age, gender
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An unstructured covariance matrix was used owing to 
uncertainty regarding immune parameter correlations 
in psychosis. Analyses were only performed if  ≥3 studies 
were identified. A 2-tailed P value <.05 was deemed sig-
nificant. All analyses were conducted using the metafor 
package84 in the R statistical programming language.85
Meta-analysis of Variability
To measure variability, the natural log of the ratio of 
estimates of the population standard deviations for each 
group was calculated to give the log variability ratio (VR), 
as previously described (supplementary eAppendix 3).28,86 
In biological systems, variance often scales with mean.87 
Thus, between group differences in relative variability 
may, at least partially, be a function of between-group 
differences in mean. Therefore, a meta-analysis of rela-
tive variability of patient compared with control immune 
parameters scaled to group means was performed: the 
log coefficient of variation ratio (CVR) (the natural loga-
rithm of the ratio of estimates of population coefficients 
of variation).28,86 Where the mean is greater in patients 
than controls, the CVR is a more conservative estimate 
of variability. To aid interpretation, summary effect sizes 
for lnVR and lnCVR were transformed back to a linear 
scale, as previously described.28 Thus, a VR (or CVR) of 
1 indicates equal variability in patient and control groups, 
a VR (or CVR) greater than 1 indicates greater relative 
variability in patient groups, and a VR (or CVR) less than 
1 indicates lower relative variability in patient groups.
Meta-analysis of Mean Differences
A meta-analysis of between group differences in immune 
parameters was performed, indexed using Hedges g. 
A  random effects model was used owing to expecta-
tion of heterogeneity across studies. Data were log-
transformed before meta-analysis, since the Cochrane 
Collaboration recommends log transformation for nor-
malization of positive skew.58 Log-transformed data were 
either extracted directly from manuscripts, or following 
provision of raw study-level data by authors which we 
subsequently log-transformed. Where log-transformed 
study level/summary data were unavailable, log-transfor-
mation estimates were calculated as described by Higgins 
and colleagues.61
Sensitivity Analyses
To determine if  findings were influenced by confounding, 
we aimed to perform sensitivity analyses to determine if  
findings remained in studies that matched patients and 
controls for BMI, smoking, age, gender, ethnicity, and 
HPA axis activity. We also performed sensitivity analyses 
excluding poor quality studies.
To determine if  findings were influenced by data-skew, 
we conducted sensitivity analyses after excluding data sets 
that met Cochrane criteria for skew despite log transfor-
mation.61,88 The skew ratio of each immune parameter for 
patients and controls was determined using the following 
calculation: lowest possible value for each parameter sub-
tracted from observed mean, divided by standard devia-
tion. A ratio of <1 provides strong evidence of skew,61,88 
and, consequently, studies with a ratio <1 were removed 
in sensitivity analyses.
To determine if  there was a difference in proportion of 
skewed data between patients and controls (which could 
influence variability analyses), for each immune param-
eter, the proportion of data sets with severe skew in 
Study Patient, N Control, N Diagnoses Patient Age, Mean (SD)
Immune 
Parameter Matching
Petrikis et al57 39 39 Schizophrenia 
Schizophreniform 
disorder
Brief  psychotic disorder
27.0
SD not specified
IL6, IL17, TGFβ Age, gender, 
BMI, smoking
Rapaport and Lohr76 12 14 Schizophrenia 37.9 (11.6) sIL2R Age, gender, 
ethnicity
Şimşek et al77 30 26 Schizophrenia
Schizophreniform 
disorder
14.7
1.9
IL2, IL4, IL6, 
IL10, IL17, 
TNFα, IFNγ
Age, gender, 
BMI, smoking
Sperner-Unterweger 
et al58
21 16 Schizophrenia 26.8 (5.5) Total lymphocyte 
count
Not specified
Sirota et al59 6 22 Schizophrenia Not specified sIL2R Age, gender
Song et al78 83 65 Schizophrenia 27.3 (6.7) IL1β, TNFα Age, gender, 
BMI, smoking
Song et al79
Song et al80
62 60 Schizophrenia 24.7 (5.5) IL1β, IL6, TNFα Age, gender, 
BMI, smoking
Theodoropoulou et al81 53 62 Schizophrenia Not specified IL1β, IL2, TNFα Age, gender
Xiu et al82 128 62 Schizophrenia 25.8 (9.4) IL10 Age, gender, 
BMI, smoking, 
ethnicity
Table 1. Continued
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patients and controls was compared using Fisher’s exact 
test.89
Consideration of Publication Bias, Study Inconsistency, 
and Study Quality
Publication bias was assessed for mean differences in 
all parameters by visual inspection of funnel plots of 
standard errors against immune residuals. We did not 
assess for publication bias related to variability, as a 
selective publication bias is extremely unlikely to exist 
for such measures. Study quality was assessed using the 
Newcastle-Ottawa Scale (NOS) (supplementary eAppen-
dix 4).61,90 The thresholds for converting NOS scores into 
“good,” “fair,” and “poor” quality followed criteria previ-
ously described by systematic reviews91 sponsored by the 
US Agency for Healthcare Research and Quality (supple-
mentary eAppendix 4). Analyses were repeated with poor 
quality studies removed. Inconsistency between studies 
was assessed using the I2 statistic (supplementary eAp-
pendix 3).92
Consideration of Raw Data Distribution
For patients and controls, distribution of raw data sets 
(with >10 data points) for each immune parameter was 
visually examined using kernel density plots. Studies 
providing data for the same immune parameter were 
examined on the same kernel density plot, with val-
ues first normalized (mean-scaled). Hartigan’s Dip Test 
of Unimodality93 was employed to assess the probabil-
ity of immune parameter data following a unimodal 
distribution.
Results
Study Selection
Of 3905 citations retrieved, 3751 were excluded after title/
abstract review (supplementary eFigure  1). Following 
manuscript review, 115 studies were excluded based on 
failure to meet inclusion criteria. All studies included 
were cross-sectional. IL2 and IL10 data for patients and 
controls from 2 data sets54–57 were excluded owing to insuf-
ficient data to allow mean/standard deviation calculation. 
The final data set included 35 publications,26,40–60,69–82 mak-
ing up 32 study data sets providing data on 188 immune 
measures (number of measures is greater than number of 
data sets because subjects had more than one measure in 
many studies). The total sample consisted of 2733 peo-
ple (1263 patients, 1470 controls; Table 1, supplementary 
eFigure 1 and supplementary eTable 1), allowing meta-
analysis of IL1β, IL2, sIL2R, IL4, IL6, IL8, IL10, IL17, 
TNFα, IFNγ, TGFβ, CRP, and total lymphocyte count. 
We received responses from authors of 15 studies, either 
providing raw data or clarification regarding data modal 
distribution/medication status.26,40–43,45,49–52,54–57,74 Raw data 
were obtained for 13 studies.26,41–43,49–52,54–57,74 After exclu-
sion of data with <10 data points,26,43,50 there were suf-
ficient data to separately analyze the distribution of 65 
immune measures (32 in patients, 33 in controls) pertain-
ing to IL2, IL4, IL6, IL8, IL10, TGFβ, TNFα, IFNγ, 
and CRP. The total sample for raw data analysis was 691 
(389 patients, 302 controls).
Variability Ratio
We found a significant overall effect of  group on 
log variability ratio across all immune parameters 
(χ2 = 150.33, P < .0001). Figure 1 shows that the varia-
bility of  FEP was significantly reduced compared with 
controls for the following parameters: IL1β (VR = 0.35; 
95% CI = 0.17–0.72; P = .004); IL6 (VR = 0.19; 95% 
CI  =  0.09–0.43; P < .0001); IL8 (VR  =  0.28; 95% 
CI  =  0.15–0.52; P < .0001); TNFα (VR  =  0.36; 95% 
CI  =  0.17–0.75; P = .01); and IL4 (VR  =  0.55; 95% 
CI  =  0.32–0.94; P = .03). Variability was not signifi-
cantly altered for: IL17 (VR  =  0.61; 95% CI  =  0.35–
1.08; P = .09); CRP (VR = 0.82; 95% CI = 0.45–1.47; 
P = .50); IFNγ (VR = 0.62; 95% CI = 0.25–1.50; P = 
.29); IL10 (VR = 0.58; 95% CI = 0.27–1.21; P = .15); 
IL2 (VR = 0.31; 95% CI = 0.09–1.13; P = .08); TGFβ 
(VR  =  0.99; 95% CI  =  0.59–1.65; P = .97); sIL2R 
(VR = 0.79; 95% CI = 0.48–1.32; P = .38); and total 
lymphocyte cell count (VR  =  0.33; 95% CI  =  0.08–
1.25; P = .10).
Coefficient of Variation Ratio
We found a significant overall effect of group on log variabil-
ity ratio across all immune parameters (χ2 = 68.62, P < .0001). 
Figure 2 shows that significant variability differences found 
with VR remained present using CVR for IL6 (CVR = 0.64; 
95% CI = 0.52–0.79; P < .0001) and IL8 (CVR = 0.83; 95% 
CI = 0.74–0.93; P = .001). There was no significant difference 
found in variability of CRP (CVR = 1.12; 95% CI = 0.84–
1.49; P = .46), IFNγ (CVR = 1.16; 95% CI = 0.83–1.62; P 
= .39), IL10 (CVR = 0.88; 95% CI = 0.71–1.08; P = .23), 
IL2 (CVR  =  1.00; 95% CI  =  0.58–1.73; P = .99), IL17 
(CVR = 1.13; 95% CI = 0.96–1.33; P = .13), and total lym-
phocyte count (CVR = 0.37; 95% CI = 0.10–1.42; P = .15), 
consistent with VR results. However, differences in variabil-
ity for IL1β (CVR = 0.87; 95% CI = 0.57–1.33; P = .52), 
IL4 (CVR = 0.71; 95% CI = 0.48–1.07; P = .10), and TNFα 
(CVR = 0.97; 95% CI = 0.76–1.23; P = .79), shown to be 
significantly less variable in patients as per VR results, were 
not significant using CVR. Moreover, variability of TGFβ, 
previously shown in VR analysis to be no different between 
groups, was more variable in patients according to CVR 
analysis (CVR = 1.41; 95% CI = 1.09–1.83; P = .01). This 
suggests IL1β, TNFα, IL4, and TGFβ variability analyses 
are influenced by mean scaling.
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Mean Differences in Immune Measures
We found a significant overall effect of group on mean lev-
els across all immune parameters (χ2 = 114.49, P < .0001). 
Figure 3 shows that significant elevations in the following 
parameters were observed in FEP: IFNγ (g = 0.32; 95% 
CI = 0.11–0.53; P = .003); IL17 (g = 0.48; 95% CI = 0.06–
0.89; P = .03); IL6 (g = 0.62; 95% CI = 0.32–0.92; P < 
.0001); TGFβ (g = 0.53; 95% CI = 0.18–0.88; P = .003); 
and TNFα (g  =  0.56; 95% CI  =  0.22–0.90; P  =  .001). 
There were no significant differences between groups for: 
CRP (g = 0.66; 95% CI = −0.03 to 1.34; P = .06); total 
lymphocyte count (g  =  0.31; 95% CI  =  −0.13 to 0.76; 
P = .17); IL10 (g = 0.24; 95% CI = −0.13 to 0.62; p = 
.20); IL1β (g = 0.49; 95% CI = −0.13 to 1.11; P = .12); 
IL2 (g = −0.07; 95% CI = −0.53 to 0.39; P = .77); IL4 
(g = 0.23; 95% CI = −0.05 to 0.51; P = .10); IL8 (g = 0.04; 
Figure 2. Forest plot showing effect sizes for mean-scaled variability of immune parameters in antipsychotic-naïve first-episode psychosis 
compared with healthy controls. The coefficient of variation ratio (CVR) was significant decreased for interleukin 6 (IL6) and interleukin 
8 (IL8), indicating lower variability of these immune parameters in patients compared with controls, and significantly increased for 
transforming growth factor beta (TGFβ), indicating increased variability of this immune parameter in patients compared with controls.
Figure 1. Forest plot showing effect sizes for variability ratio (VR) of immune parameters in antipsychotic-naïve first-episode psychosis 
compared with healthy controls. The VR was significantly decreased for interleukin 4 (IL4), interleukin 1beta (IL1β), interleukin 6 
(IL6), interleukin 8 (IL8), and tumor necrosis factor alpha (TNFα), indicating lower variability of these immune parameters in patients 
compared with controls.
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95% CI = −0.62 to 0.70; P = .90); and sIL2R (g = 2.66; 
95% CI = −0.03 to 5.34; P = .05).
Sensitivity Analysis of the Influence of Confounders
Restricting analysis of mean differences to studies that 
matched for age, gender, BMI, and smoking created a 
data set of 8 studies, covering data on 44 immune meas-
ures (supplementary eFigure  2). Analysis showed ele-
vated IL6 (g = 0.83; 95% CI = 0.21–1.45; P = .01), IL17 
(g  =  0.68; 95% CI  =  0.09–1.28; P = .02), and IFNγ 
(g = 0.54; 95% CI = 0.27–0.80; P < .001) in patients, and 
no significant difference in TNFα, IL10, or IL1β levels 
between groups. These findings are consistent with the 
primary meta-analysis, apart from the TNFα outcome, 
which was no longer significant, suggesting it could be 
influenced by confounding. There were insufficient data 
to analyze IL2, sIL2R, IL4, IL8, TGFβ, CRP, and lym-
phocyte levels. Sensitivity analyses matching for ethnicity 
and stress were not possible owing to insufficient stud-
ies. We combined CRP and hsCRP data a priori (supple-
mentary eAppendix 3). Poor sensitivity of the CRP assay 
could conceivably mask hsCRP outcomes. Re-analysis of 
hsCRP data alone suggests this is not the case, with no 
difference in hsCRP levels between patients and controls 
(g = 0.87; 95% CI = 0.17–1.91; P = .10).
Sensitivity Analysis of the Influence of Residual Skew
Removing studies with evidence of persistent skew despite 
log transformation created a data set of 27 studies, cov-
ering data on 118 immune measures (supplementary 
eFigure 3). Analysis showed elevated IL6 (g = 0.77; 95% 
CI = 0.15–1.40; P = .02), TNFα (g = 0.58; 95% CI = 0.08–
1.09; P = .02), TGFβ (g = 0.68; 95% CI = 0.28–1.08; P < 
.01), IFNγ (g = 0.24; 95% CI = 0.01–0.48; P = .04), and 
IL17 (g = 0.64; 95% CI = 0.15–1.14; P = .01) in patients, 
and no significant difference in IL2, IL4, IL10, CRP, or 
total lymphocyte count between groups, consistent with 
our primary meta-analysis. In contrast to the primary 
analysis, IL1β (g = 0.96; 95% CI = 0.39–1.52; P < .01), 
sIL2R (g = 0.93; 95% CI = 0.14–1.71; P = .02), and IL8 
(g = 0.87; 95% CI = 0.24–1.49; P = .01) were elevated in 
patients.
For all immune parameters, there was no significant 
difference in the proportion of immune measures with 
severe skew in patients compared with controls, either 
in raw-scaled (P = .20–.99) or log-transformed data sets 
(P = .21–.99) (supplementary eTable 2).
Study Quality
Newcastle Ottawa Scale quality scores ranged from 0 to 
8 (supplementary eTable 3). Of 32 samples, 24 were rated 
as “good-quality,” 4 as “fair-quality,” and 4 as “poor-
quality.”50,53,58,60 Of 3 studies examining total lymphocyte 
counts, 2 were poor quality.53,58 Excluding the poor-qual-
ity paper50 from CRP meta-analysis did not alter out-
comes for meta-analysis of mean difference (g  =  0.76; 
95% CI = −0.01 to 1.53; P = .05). Excluding this study 
from variability analyses for CRP showed reduced vari-
ability in patients (VR = 0.60; 95% CI = 0.45–0.80; P = 
.001), although there was no difference when mean-scaled 
(CVR = 1.09; 95% CI = 0.79–1.50; P = .61). Excluding 
Figure 3. Forest plot showing effect sizes for mean differences in immune parameters in antipsychotic-naïve first-episode psychosis 
compared with healthy controls. There was a significant elevation in interferon gamma (IFNγ), interleukin 17 (IL17), interleukin 6 (IL6), 
transforming growth factor beta (TGFβ), and tumor necrosis factor alpha (TNFα) in patients compared with controls. There was no 
significant difference in C-reactive protein (CRP), interleukin 10 (IL10), interleukin 1beta (IL1β), interleukin 2 (IL2), interleukin 4 (IL4), 
interleukin 8 (IL8), soluble interleukin 2 receptor (sIL2R), and total lymphocyte count (TLC) in patients compared with controls.
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the poor-quality paper60 from sIL2R meta-analysis did 
not significantly alter outcomes for meta-analysis of 
mean-difference (g = 3.28; 95% CI = 0.06–6.50; P = .05) 
nor variability analyses.
Publication Bias and Study Inconsistency
The funnel plot for publication bias did not show evi-
dence of asymmetry (supplementary eFigure  4).26 
Higgins’ I2 inconsistency values (supplementary eTable 4) 
demonstrated a medium-large degree of inconsistency for 
all parameters, apart from low levels of inconsistency for 
IFNγ.
Distribution of Raw Immune Parameter Data
Visual inspection of kernel density plots suggested right 
skewed unimodal distribution for all immune measures 
in FEP and controls (supplementary eFigure  5). For 
patients, 30 of 32 immune measures (94%) met Hartigan’s 
Dip Test criteria for unimodal distribution (supplemen-
tary eTable 5), including data sets for IL2, IL4, IL6, IL8, 
IL10, TGFβ, TNFα, IFNγ, and CRP. For healthy con-
trols, 33 of 33 immune measures (100%) met Hartigan’s 
Dip Test criteria for unimodal distribution (supplemen-
tary eTable 5), including data sets for IL2, IL4, IL6, IL8, 
IL10, TGFβ, TNFα, IFNγ, and CRP. In the patient 
group, 1 of the 6 data sets examining IL6 met criteria for 
a multimodal distribution,54–56 and 1 of the 3 data sets 
examining IFNγ met criteria for a multimodal distribu-
tion.49,74 These 2 data sets did not have overlapping sam-
ples and multimodality for IL6 was not accompanied by 
multimodality for IFNγ (supplementary eTable 5).
Discussion
Summary of Findings
Our first main finding is that that there is a significant 
reduction in variability of IL1β, IL4, IL6, IL8, and 
TNFα in FEP patients compared with controls, which 
is not explained by mean scaling for IL6 and IL8. After 
adjusting for mean scaling, there was increased hetero-
geneity of TGFβ in patients compared with controls. As 
there is no significant difference in proportion of stud-
ies with strong evidence of skewed data in patients com-
pared with controls for all parameters, these variability 
outcomes do not appear to be the result of reduced data 
skew in patients, and thus may reflect intrinsic differences 
in immune variability. An examination of raw data did 
not provide strong evidence for multimodal data distribu-
tion of immune parameters in either patients or controls.
We found elevated IL6, TNFα, IFNγ, TGFβ, and IL17 
levels in patients compared with controls with small-
medium effect sizes (range: g  =  0.32–0.62). IL6, IFNγ, 
and IL17 outcomes were robust to sensitivity analyses, 
indicating these alterations are unlikely to be driven by 
key potential confounders and data skew.
The absence of variability elevations of most immune 
parameters in patients compared to controls and the 
absence of multimodal distribution of most data is evi-
dence against the existence of an immune subgroup of 
psychosis. Lower variability of IL6 in patients, coupled 
with a robust difference in mean concentration, could 
instead be interpreted as this parameter representing a 
core (or at least more uniformly present) component in 
the immunobiology of psychosis.
Strengths and Limitations
By focusing on antipsychotic-naïve FEP, we limited dura-
tion of secondary illness-related factors known to influ-
ence immune parameters, eg, antipsychotics,67 poor diet, 
and reduced exercise levels.30,31 Furthermore, sensitivity 
analyses focusing on studies with strict environmental 
and physiological matching provides greater confidence 
that FEP is associated with elevated immune param-
eters. Relative to previous meta-analyses in the field, log-
transformation to reduce influence of skew on summary 
effect sizes followed by sensitivity analysis excluding 
data with persistent evidence of skew provides us with 
robust evidence that immune alterations are present even 
when influence of data skew is reduced. Moreover, use 
of a multivariate meta-analytic approach that models the 
covariance of immune parameters and allows omnibus 
testing of results thereby reducing multiplicity concerns, 
is a strength. Gaining access to raw data to examine 
distribution of multiple data sets is a further strength, 
complementing findings of the variability meta-analysis. 
Finally, since in biological systems variance often scales 
to mean,87 performing a mean-scaled (CVR) variability 
meta-analysis to complement the primary meta-analysis 
of variability (VR) provides a conservative approach to 
assess if  primary outcomes are influenced by mean group 
differences, and provides greater confidence regarding 
the outcome of increased homogeneity of IL6 and IL8 in 
patients compared with controls.
It should be noted that there is diagnostic heterogeneity 
in first-episode samples. In general, about two-thirds of 
FEP patients have a diagnosis of schizophrenia, while the 
remainder are diagnosed with other psychotic disorders.94 
Of the 32 samples, 18 (56%) included patients with schiz-
ophrenia alone (table 1). The remaining samples poten-
tially also included affective psychosis. The proportion of 
individuals with nonaffective psychosis was not defined, 
precluding us conducting sensitivity analyses of the effect 
of diagnosis. Therefore, our findings should not be taken 
as specific to schizophrenia, but representative of FEP in 
general. Future studies should provide greater clarity as 
to whether patients included in analyses presented with 
an affective or nonaffective psychosis. The combination 
of affective and nonaffective psychosis in variability anal-
yses should increase heterogeneity in patients and might 
be expected to influence the modal distribution of patient 
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immune data. However, there was reduced variability of 
several immune parameters in patients, and no strong 
evidence for multimodal distribution of patient immune 
data. Indeed, inclusion of affective psychosis within 
patient samples may have resulted in under-estimation 
of increased homogeneity of immune variability in this 
group, compared with controls.
Inconsistency between studies was moderate to high. 
This could reflect methodological factors, eg, differences 
in assay sensitivity, and use of serum/plasma sampling. 
However, the random effects model used is robust to 
inconsistency, and would not explain our variability find-
ings, because these reflect within-study variation (where 
methodologic factors are the same in both patient and 
control groups in any given study). Moreover, although 
we were stringent in selecting antipsychotic naïve patients, 
confirmation of naivety for all psychiatric medications 
was not universally stated. Thus, use of treatments 
beyond antipsychotics may have confounded results con-
tributing to inconsistency. Future prospective studies are 
required that control stringently for medication thereby 
addressing this potential confound.
Although sample sizes are larger than previous meta-
analyses, relatively small sample sizes persist for measures 
of sIL2R (n = 156), TGFβ (n = 234), and lymphocytes 
(n = 236). Thus, conclusions regarding these parameters 
are less secure, and further studies required. Furthermore, 
only 8 out of 32 (25%) studies matched simultaneously for 
age, gender, smoking, and BMI, and 2 sensitivity analyses, 
matching for ethnicity and stress, were not possible owing 
to insufficient studies. Other factors that could be differ-
ent between the groups and influence immune measures 
include recreational substance exposure95 and subclinical 
physical comorbidity.96–98 Information on these was not 
included in most studies, precluding sensitivity analy-
sis. Future studies should aim to match patients appro-
priately to reduce impact of these potential confounds. 
Moreover, controls may be unusually healthy compared 
with the general population because they are screened 
for illnesses, potentially inflating effect sizes for mean dif-
ferences.99 However, inclusion of super-healthy controls 
would reduce variability of control immune parameters. 
In fact, we observed the opposite, and the inclusion of 
“super controls” could even have led to an under-estimate 
of reduced variability in immune measures in patients. 
There is the potential for variability analyses to have been 
influenced by the presence of latent immune subgroups 
within the control population. We are however reassured 
by our findings that 100% of raw control data examined 
met criteria for unimodal distribution.
Although all studies included in analyses used well-
validated quantification techniques (supplementary 
eTable 6), insufficient assay sensitivity may have limited 
ability to detect subtle differences in immune param-
eters between groups, particularly for titers beneath the 
limit of assay detection. However, where we could assess 
impact of poor assay sensitivity, examining hsCRP lev-
els separate from CRP levels, results were unaltered. 
Future developments in immunoassay technology which 
bring greater assay sensitivity100 will potentially provide 
greater clarity as to the nature of immune alterations in 
psychosis.
Positive data skew can inflate standard deviation owing 
to the presence of outliers within the “tail” of the data.101 
We observed evidence of data skew in patients and/or 
controls for all immune parameters except IL8, TGFβ, 
and lymphocyte count (supplementary eTable  2). For 
remaining immune parameters, residual data skew may 
have influenced variability analyses. However, we demon-
strated no significant difference in proportion of skewed 
data between groups, suggesting that differences in skew 
in controls compared with patients do not explain varia-
bility differences. Moreover, skew does not always inflate 
standard deviations, since skew describes the shape of 
data distribution, not scale of spread.94
Comparison With Previous Meta-analyses
A summary of results from previous meta-analyses exam-
ining mean differences in immune parameters in FEP16–22 
is provided in supplementary eTable 7. There are 2 key 
differences when compared with previous meta-analyses. 
First, we failed to observe any differences between patients 
and controls for mean levels of IL1β, sIL2R, IL4, IL8, 
IL10, total lymphocyte count, and CRP. However, IL1β, 
sIL2R, and IL8 levels were elevated in sensitivity analyses 
excluding data with evidence of skew. These sensitivity 
analyses are limited by reduced sample size, but suggest 
the need for future research to determine whether differ-
ences in these immune parameters exist between FEP and 
controls. Second, where differences were observed, effect 
size estimates were generally smaller than those in previ-
ous meta-analyses. For example, Upthegrove et al19 pre-
viously reported effect sizes of 2.21 and 0.94 for elevated 
IL6 and TNFα, respectively in antipsychotic-naïve FEP 
compared with controls, whereas we observed effect sizes 
of 0.62 and 0.56, respectively. These differences may be a 
consequence of several factors, including increased sam-
ple size (participant numbers increasing by up to 7-fold), 
use of log transformed data, and a multivariate meta-
analytic approach that models covariance of immune 
parameters. Given the additional sample size, the focus 
on antipsychotic naïve patients, the statistical approach 
employed, and steps we have taken to assess the influence 
of data-skew and physiological confounds, we suggest 
that our updated results are likely the most reliable esti-
mates of peripheral immune alterations in FEP to date.
Interpretation and Implications
Our findings suggest that an immune subtype of psychosis, 
if  present, cannot currently be identified through exam-
ination of peripheral immune parameter distribution. 
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Indeed, our results could instead be interpreted as sup-
porting the hypothesis that alterations in the immune sys-
tem are a general feature of psychosis.102
Our results cannot however exclude the possibility 
that there are alterations in other aspects of the immune 
system specific to a subgroup of patients. An immune 
subgroup could manifest itself  via various peripheral 
patterns. Firstly, an immune subgroup might result in 
wider spread of data points (increased heterogeneity) in 
patients compared with healthy controls, although, with 
the potential exception of TGFβ, this is not observed 
in the current meta-analysis. Secondly, subgroups of 
patients defined by step increases in immune parameter 
concentrations could result in multimodal distribution of 
immune parameter data. Modal analyses in this article 
suggest a unimodal distribution for most immune param-
eters, although there was some evidence, albeit weak, for a 
multimodal distribution of IL6 and IFNγ. Thirdly, a pro-
portion of patients may be more vulnerable to the impact 
of immune activation, inducing inflammatory and thence 
psychopathological sequelae in that group (even if  proin-
flammatory titers are of a similar magnitude compared 
with controls). The observation of increased variabil-
ity of TGFβ levels in FEP compared with controls fol-
lowing mean scaling could reflect alterations in immune 
regulatory pathways in a subgroup of individuals with 
FEP, supporting this model. TGFβ can (although not 
always)103 perform an anti-inflammatory role, including 
inhibition of cytokine production from macrophages104 
and inhibition of B-lymphocyte proliferation.105 Thus, 
patients with an impaired TGFβ-mediated immune 
response could potentially be vulnerable to proinflam-
matory effects that characterize psychosis (ie, homoge-
nous increases in IL6). Moreover, genetic variants in the 
TGFβ gene TGFB1 influence susceptibility for schiz-
ophrenia.106 Fourthly, immune susceptibility may arise 
through a unique network-effect of multiple cytokines to 
bring about inflammatory sequelae and thence psychopa-
thology. Indeed, Weickert and colleagues have employed 
cluster analysis to divide patients with schizophrenia-
spectrum disorders into subgroups based on elevation of 
multiple cytokines in unison.27,29 They have observed that, 
compared with controls, a greater proportion of patients 
clustered within an “elevated cytokine subgroup.” Jeffries 
and colleagues107 have used graph theory to examine net-
work connectivity of blood proteins related to neuro-
immunology across the psychosis spectrum, observing 
that protein correlation networks can successfully dif-
ferentiate between controls, and prodromal individuals 
who transition/do not transition to psychosis. Based on 
the current meta-analysis, we are unable to comment on 
whether there is a FEP immune subgroup characterized 
by an abnormal immune parameter network.
The findings of elevated IL6, IL17, and IFNγ in psy-
chosis appear robust, as elevations are also seen in sen-
sitivity analyses, indicating they are unlikely due to 
confounding or other nonspecific factors. Elevations of 
these 3 cytokines could point toward activation of both 
innate and adaptive immune responses.108,109 Moreover, 
of these 3 cytokines, IL6 shows reduced variability in 
patients (including after mean scaling), suggesting this 
could be a core component of the pathophysiology of 
psychosis. IL6 is a multifunctional cytokine playing a role 
in inflammation and the acute phase response,110 immune 
response,111–113 hematopoiesis,114 glucose and lipid metab-
olism,115 and bone-turnover.116 It crosses the blood–brain 
barrier (BBB),117 and there is evidence of increased cere-
brospinal fluid (CSF) IL6 levels in psychosis,13 indicating 
that peripheral IL6 could influence brain function. In the 
CNS, IL6 induces microglial proliferation118 and activa-
tion.119 Microglia play a key role in synaptic remodeling, 
among other functions.120 Thus, raised peripheral IL6 
levels could activate microglia and influence secondary 
brain changes.4 Supporting this, postmortem studies have 
reported increased microglial density and morphologi-
cal changes indicative of microglial activation in schizo-
phrenia,8–10 and some, although not all, positron emission 
tomography in vivo studies have reported altered binding 
to a marker expressed on activated microglia in schizo-
phrenia and people at risk of psychosis.11,12 However, 
it is important to recognize that there are other poten-
tial models explaining the association between immune 
alterations and psychosis,98 and recent studies examin-
ing therapeutic potential of anti-IL6 immunotherapy 
in schizophrenia have been disappointing (although 
this potentially relates to the inability of the monoclo-
nal antibody to cross the BBB).121,122 Immune alterations 
could be a consequence of psychosis (eg, psychosocial 
stress activating an inflammatory response123) or simply 
an epiphenomenon. Thus, whether peripheral alterations 
are a cause or a consequence of psychosis remain to be 
determined.4 Longitudinal studies examining networks 
of immune parameters in both CSF and blood follow-
ing individuals in the prodrome through transition to 
FEP and experimental medicine studies modulating spe-
cific aspects of immune function are needed to identify 
the mechanism underlying the immune alterations we 
report, and determine the potential for targeting them 
therapeutically.
Conclusions
Antipsychotic naïve FEP is associated with elevated levels 
of IL6, IL17, and IFNγ with small-medium effect sizes 
after accounting for skew and physiological confounds. 
There is reduced variability in the levels of immune 
parameters in FEP, and there does not appear to be a 
clear multimodal distribution of immune parameters in 
patients. These findings suggest that an immune subgroup 
of psychosis cannot currently be defined by examination 
of peripheral immune data spread, and are consistent 
with elevated immune markers being typical of psychosis.
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Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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